Current Duke Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Nephrology,
Medicine
Associate Professor in Surgery
·
2025 - Present
Surgery, Abdominal Transplant Surgery,
Surgery
Recent Scholarly Works
Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet.
Journal article Hypertension · January 2026 BACKGROUND: The rice diet (RD), a low-sodium (<200 mg/d), low-protein (≈20 g/d), and low-fat (<5 g/d) diet was used to treat patients with malignant hypertension beginning in the 1940s, before any effective antihypertensive drugs were available. We retrosp ... Full text Open Access Link to item CiteRice Diet Improves Survival, Blood Pressure, and Eye Changes in 544 Patients with Malignant-Hypertension
Preprint · 2026 Background The sodium-restricted rice diet (RD) was once the only effective treatment for malignant hypertension (MH); however, a modern, comprehensive data analysis is lacking. We determined patient survival and ocular improvements in 544 MH pat ... Full text CitePerspectives of Patients on the Kidney Transplant Waitlist Regarding Willingness to Undergo Xenotransplantation.
Journal article Xenotransplantation · 2026 BACKGROUND: Xenotransplantation, the use of genetically modified pigs as organ donors, is entering clinical trials in kidney transplantation. Although the medical community has long considered xenotransplant a potential solution to the organ shortage, the ... Full text Link to item CiteRecent Grants
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE)
Clinical TrialPrincipal Investigator · Awarded by Biogen MA, Inc. · 2026 - 2031Targeting the B Cell Response to Treat Antibody-Mediated Rejection
ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2028A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Clinical TrialPrincipal Investigator · Awarded by Biogen MA, Inc. · 2025 - 2026View All Grants
Education
Case Western Reserve University, School of Medicine ·
2002
M.D.